Advances in the treatment of relapsing - Remitting multiple sclerosis

Biomedical Journal

Volumn 37, Issue 2, 2014, Pages 41-49

  Tanasescu, Radu ^a,b   Ionete, Carolina ^c   Chou, I Jun ^a,d   Constantinescu, Cris S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c UNIVERSITY OF MASSACHUSETTS   (United States)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Disease modifying treatments; Monoclonal antibodies; Multiple sclerosis; Oral drugs

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; LIVER ENZYME; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; PLACEBO; RITUXIMAB; TERIFLUNOMIDE; BETA INTERFERON; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADD ON THERAPY; ALGORITHM; ALOPECIA; ARTICLE; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HERPES SIMPLEX; HOT FLUSH; HUMAN; HYPERTENSION; LIVER TOXICITY; LOW DRUG DOSE; MOUTH ULCER; MULTIPLE SCLEROSIS; NAUSEA; NONHUMAN; PERSONALIZED MEDICINE; RELAPSE; SINGLE DRUG DOSE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; ANIMAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RISK ASSESSMENT;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RISK ASSESSMENT;

EID: 84898988480     PISSN: 23194170     EISSN: None     Source Type: Journal    
DOI: 10.4103/2319-4170.130440     Document Type: Article

References (94)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17.
2. Ogura H, Arima Y, Kamimura D, Murakami M. The gateway theory: How regional neural activation creates a gateway for immune cells via an inflammation amplifier. Biomed J 2013;36:269-73.
3. Stys PK, Zamponi GW, van Minnen J, Geurts JJ. Will the real multiple sclerosis please stand up? Nat Rev Neurosci 2012;13:507-14.
4. Evangelou N. The only way to manage neurodegeneration in MS is to prevent it with effective anti-inflammatory therapy: Yes. Mult Scler 2012;18:1680-1.
5. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
6. Jeffery DR. Recent advances in treating multiple sclerosis: Efficacy, risks and place in therapy. Ther Adv Chronic Dis 2013;4:45-51.
7. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, et al. Oral Fingolimod (FTY720) Reduces the Rate of Relapses That Require Steroid Intervention or Hospitalization Compared with Intramuscular Interferon beta-1a: Results from a Phase III Study (TRANSFORMS) in Multiple Sclerosis. Neurology 2010;74:A552.
8. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. N Engl J Med 2010;362:387-401.
9. Lugaresi A, di Ioia M, Travaglini D, Pietrolongo E, Pucci E, Onofrj M. Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat 2013;9:893-914.
10. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
11. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9.
12. Duquette P, Girard M, Despault L, Dubois R, Knobler RL, Lublin FD, et al. Interferon Beta-1b Is Effective in Relapsing-Remitting Multiple-Sclerosis- Clinical-Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Neurology 1993;43:655-61.
13. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94.
14. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504.
15. Ali R, Nicholas RS, Muraro PA. Drugs in development for relapsing multiple sclerosis. Drugs 2013;73:625-50.
16. Ziemssen T, Schrempf W. Glatiramer acetate: Mechanisms of action in multiple sclerosis. Int Rev Neurobiol 2007;79:537-70.
17. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 2001;57:S16-24.
18. Comi G, Filippi M, Wolinsky JS, Aceta EC. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-7.
19. Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010;16:342-50.
20. Oh J, Calabresi PA. Emerging injectable therapies for multiple sclerosis. Lancet Neurol 2013;12:1115-26.
21. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. The N Engl J Med 2006;354:899-910.
22. Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007;68:1390-401.
23. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23.
24. Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, et al. Requirement for safety monitoring for approved MS therapies-An overview. Clin Exp Immunol 2014;175:397-407.
25. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80.
26. Li JM, Yang Y, Zhu P, Zheng F, Gong FL, Mei YW. Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells. Immunopharmacol Immunotoxicol 2012;34:36-41.
27. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW, Therapeutics, Technology Assessment Subcommittee of the American Academy of N. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74:1463-70.
28. Tanasescu R, Debouverie M, Pittion S, Anxionnat R, Vespignani H. Acute myeloid leukaemia induced by mitoxantrone in a multiple sclerosis patient. J Neurol 2004;251:762-3.
29. Pratt RG, Boehm GA, Kortepeter CM, Racoosin JA. Mitoxantrone treatment of multiple sclerosis: Safety considerations. Neurology 2005;65:1997.
30. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74:1463-70.
31. Rivera V, Weinstock-Guttman B, Beagan J, Al-Sabbagh A, Bennett R, Dangond F. Final results from the registry to evaluate novantrone effects in worsening multiple sclerosis study. Mult Scler 2009;15:S254-5.
32. Chun J, Hartung HP. Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis. Clin Neuropharmacol 2010;33:91-101.
33. Zemann B, Kinzel B, Muller M, Reuschel R, Mechtcheriakova D, Urtz N, et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 2006;107:1454-8.
34. Aktas O, Kury P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 2010;6:373-82.
35. Mehling M, Lindberg RL, Kuhle J, Vedrine C, Kappos L, Brinkmann V. Oral fingolimod (FTY720) treatment reduces peripheral IL-17-producing TH17 cells in patients with multiple sclerosis. Mult Scler 2008;14:S234-S.
36. Buzzard KA, Broadley SA, Butzkueven H. What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis? Int J Mol Sci 2012;13:12665-709.
37. Mehling M, Kappos L, Derfuss T. Fingolimod for multiple sclerosis: Mechanism of action, clinical outcomes, and future directions. Curr Neurol Neurosci 2011;11:492-7.
38. Cohen J, Barkhof F, Comi G, Hartung HP, Kappos L, Khatri B, et al. Oral Fingolimod (FTY720) Treatment improves the performance of daily activities compared with intramuscular interferon beta-1a: Patient-Reported Indices for Multiple Sclerosis (PRIMUS)-Activities Results from a Phase III Study (TRANSFORMS). Neurology 2010;74:A543-4.
39. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15.
40. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: A randomised extension of the TRANSFORMS study. Lancet Neurol 2011;10:520-9.
41. Miller D, Cree B, Dalton C, Freedman M, Hartung H, Kappos L, et al. Study Design and Baseline Characteristics of the INFORMS Study: Fingolimod in Patients with Primary Progressive Multiple Sclerosis. Neurology; 80(Meeting Abstracts 1): P07.116.
42. EMA.2012. Available from: http://www.emea.europa.eu/ docs/en-GB/document- library/Medicine-QA/2012/04/ WC500125689.pdf EEMAqaaotroGdrnEEHCA. [Last accessed on 2013 Nov 10].
43. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm303192.htm FFdscrrfcmauomsdGfF. [Last accessed on 2013 Nov 10].
44. Tanasescu R, Evangelou N, Constantinescu CS. Role of oral teriflunomide in the management of multiple sclerosis. Neuropsychiatr Dis Treat 2013;9:539-53.
45. O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Paty DW, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894-900.
46. Freedman MS, Wolinsky JS, Wamil B, Confavreux C, Comi G, Kappos L, et al. Teriflunomide added to interferon-beta in relapsing multiple sclerosis: A randomized phase II trial. Neurology 2012;78:1877-85.
47. Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 2012;18:1278-89.
48. O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303.
49. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: Results of a prospective multicentre study. Br J Dermatol 1998;138:456-60.
50. Available from: http://www.ema.europa.eu/ema/index. jsp-curl=pages/ medicines/human/medicines/002514/human- med-001645.jsp&mid= WC0b01ac058001d124. [Last accessed on 2014 Feb 15].
51. Available from: http://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm319277.htm. [Last accessed on 2014 Feb 15].
52. Linker RA, Lee DH, Ryan S, van Dam AM, Conrad R, Bista P, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011;134:678-92.
53. Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;372:1463-72.
54. Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, et al. Effect of BG-12 on contrast-enhanced lesions in patients with relapsing - remitting multiple sclerosis: Subgroup analyses from the phase 2b study. Mult Scler 2012;18:314-21.
55. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al.; DEFINE Study Investigators. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107.
56. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
57. Available from: http://www.fda.gov/newsevents/newsroom/ pressannouncements/ucm345528.htm-source=govdelivery. [Last accessed on 2014 Feb 15].
58. Available from: http://www.ema.europa.eu/ema/index. jsp-curl=pages/ medicines/human/medicines/002601/human-med-001657.jsp&mid= WC0b01ac058001d124. [Last accessed on 2014 Feb 15].
59. Brueck W, Wegner C. Insight into the mechanism of laquinimod action. J Neurol Sci 2011;306:173-9.
60. Yang HS, Xu LY, Xiao BG , Hedlund G, Link H. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/ Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004;156:3-9.
61. Thone J, Ellrichmann G, Seubert S, Peruga I, Lee DH, Conrad R, et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 2012;180:267-74.
62. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005;64:987-91.
63. Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008;371:2085-92.
64. Filippi M, Rocca MA, Pagani E, De Stefano N, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J Neurol Neurosurg Psychiatry 2013 Sep 12. doi: 10.1136/jnnp-2013-306132. [Epub ahead of print].
65. Comi G, Jeffery D, Kappos L, Montalban X, Boyko A, Rocca MA, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012;366:1000-9.
66. Rommer PS, Stuve O, Goertsches R, Mix E, Zettl UK. Monoclonal antibodies in the therapy of multiple sclerosis: An overview. J Neurol 2008;255 Suppl 6:28-35.
67. Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, et al. The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy. J Neurol 2006;253:98-108.
68. Investigators CT, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801.
69. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: Post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011;10:338-48.
70. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, et al. Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 Clinical Trial. Neurology 2012;78:1069-78.
71. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet 2012;380:1819-28.
72. Jones JL, Coles AJ. Spotlight on alemtuzumab. Int MS J 2009;16:77-81.
73. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359:1786-801.
74. Voso MT, Pantel G, Rutella S, Weis M, D'Alo F, Urbano R, et al. Rituximab reduces the number of peripheral blood B-cells in vitro mainly by effector cell-mediated mechanisms. Haematologica 2002;87:918-25.
75. Kessel A, Rosner I, Toubi E. Rituximab: Beyond simple B cell depletion. Clin Rev Allergy Immunol 2008;34:74-9.
76. Taylor RP, Lindorfer MA. Drug insight: The mechanism of action of rituximab in autoimmune disease - the immune complex decoy hypothesis. Nat Clin Pract Rheumatol 2007;3:86-95.
77. Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, et al. Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial. Ann Neurol 2008;63:395-400.
78. Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, Parks BJ, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial. Neurology 2010;74:1860-7.
79. Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 2011;68:1156-64.
80. Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-40.
81. Stuve O, Leussink VI, Frohlich R, Hemmer B, Hartung HP, Menge T, et al. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol 2009;66:259-61.
82. Morschhauser F, Marlton P, Vitolo U, Linden O, Seymour JF, Crump M, et al. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann Oncol 2010;21:1870-6.
83. Genovese MC, Kaine JL, Lowenstein MB, Del Giudice J, Baldassare A, Schechtman J, et al. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 2008;58:2652-61.
84. Kappos L, Li D, Calabresi PA, O'Connor P, Bar-Or A, Barkhof F, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378:1779-87.
85. Tak PP, Mease PJ, Genovese MC, Kremer J, Haraoui B, Tanaka Y, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 2012;64:360-70.
86. Harigai M, Tanaka Y, Maisawa S, Group JA. Safety and efficacy of various dosages of ocrelizumab in Japanese patients with rheumatoid arthritis with an inadequate response to methotrexate therapy: A placebo-controlled double-blind parallel-group study. J Rheumatol 2012;39:486-95.
87. Rigby W, Tony HP, Oelke K, Combe B, Laster A, von Muhlen CA, et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 2012;64:350-9.
88. Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 2006;103:5941-6.
89. Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 2004;101:8705-8.
90. Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007;69:785-9.
91. Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): A phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet neurol 2010;9:381-90.
92. Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, et al. A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Daclizumab HYP Monotherapy in Relapsing-Remitting Multiple Sclerosis: Primary Results of the SELECT Trial. Neurology 2012;78.
93. Ohayon J, Oh U, Richert N, Martin J, Vortmeyer A, McFarland H, et al. CNS vasculitis in a patient with MS on daclizumab monotherapy. Neurology 2013;80:453-7.
94. Fox EJ, Rhoades RW. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Curr Opin Neurol 2012;25 Suppl:S11-9.